外周动脉疾病抗血栓治疗的成本效益分析
该回顾性研究比较了下肢血运重建后双联抗血小板治疗与双通路抗血栓抑制的临床结局和成本效益。经倾向性评分匹配后,双通路抑制组无主要不良肢体事件生存显著改善,心血管事件无差异,增量成本效益比为每QALY 30,331美元,低于美国支付意愿阈值。
要点
- 下肢血运重建后双通路抑制较双联抗血小板治疗改善无主要不良肢体事件生存。
- 双通路抑制组成本更高但健康获益更大,增量成本效益比为每QALY 30,331美元。
- 该增量成本效益比低于美国每QALY 150,000美元的支付意愿阈值。
核心结论
- 双通路抗血栓抑制与改善肢体相关结局相关,是下肢血运重建后双联抗血小板治疗的经济有效替代方案。
研究设计与样本
- 回顾性分析比较耶鲁纽黑文医院下肢血运重建后接受双联抗血小板治疗与双通路抗血栓抑制患者的特征,共审查986例患者。
- 应用4:1倾向性评分匹配调整基线差异后比较两组结局,匹配后样本量为275例。
- 成本效益在5年时间跨度内使用模型化成本和质量调整生命年评估,并计算增量成本效益比。
主要发现
- 986例下肢血运重建患者中5.6%接受双通路抗血栓抑制治疗。
- 倾向性匹配后Kaplan-Meier分析显示双通路抑制组无主要不良肢体事件生存显著改善。
- 两组无不良心血管事件生存无差异。
- 双通路抑制组成本更高(73,826美元 vs 39,548美元),但健康获益更大(4.64 vs 3.51 QALYs)。
- 增量成本效益比为每QALY 30,331美元,低于美国每QALY 150,000美元的支付意愿阈值。
关键数值与推荐
- 支付意愿阈值设定为每QALY 150,000美元,与美国卫生干预平均支付意愿一致。
- 增量成本效益比为每QALY 30,331美元,低于上述阈值,表明双通路抑制具有成本效益。
临床怎么用
- 对于下肢血运重建后患者,双通路抗血栓抑制可作为双联抗血小板治疗的经济有效替代方案。
- 决策时需权衡双通路抑制更高的成本与改善的无主要不良肢体事件生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Antithrombotic treatment plays a critical role in managing peripheral arterial disease and reducing the risk of major adverse limb events and major adverse cardiovascular events after revascularization. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is the most commonly used regimen following lower extremity revascularization (LER), but emerging studies suggest that dual antithrombotic pathway inhibition (DPI), which combines a factor Xa inhibitor with an antiplatelet agent, may offer enhanced protection. This study evaluates the clinical outcomes and cost-effectiveness of DPI compared with DAPT in patients undergoing LER. METHODS: A retrospective analysis compared the characteristics of patients treated with DAPT and DPI after LER at Yale New Haven Hospital. After applying a 4:1 propensity score matching to adjust for differences in baseline characteristics, the outcomes of the two groups were compared. Cost-effectiveness was evaluated over a 5-year horizon using modeled costs and quality-adjusted life years (QALYs), and the incremental cost-effectiveness ratio was calculated. The willingness-to-pay (WTP) threshold was set at $150,000 per QALY, which aligns with the average U.S. WTP for health interventions. RESULTS: A total of 986 patients undergoing LER were reviewed, with 5.6% on DPI. After propensity matching (N = 275), Kaplan-Meier analysis showed significantly improved major adverse limb event-free survival in the DPI group, with no difference in adverse cardiovascular event-free survival between the two groups. Although the DPI strategy incurred higher costs ($73,826 vs $39,548), it yielded greater health benefits (4.64 vs 3.51 QALYs). The incremental cost-effectiveness ratio was $30,331 per QALY, well below the U.S. WTP threshold of $150,000 per QALY, indicating that DPI is a cost-effective alternative compared with DAPT. CONCLUSIONS: DPI is associated with improved limb-related outcomes and represents a cost-effective alternative to DAPT for antithrombotic therapy after LER.
引用
- Dhanda U, Alameddine D, Schultz KS, et al. Cost-effectiveness of antithrombotic therapies for peripheral arterial disease. J Vasc Surg. 2026. PMID: 41967727. doi:10.1016/j.jvs.2026.03.629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。